



2022年3月期 第2四半期 決算参考資料
Financial Data for the 2nd quarter of FY2022
The FY2022, the year ending March 31, 2022
April 1, 2021 - March 31, 2022

| | |
|--|-------|
| 1. 連結決算概要 / Consolidated Financial Summary | 2 |
| 2. セグメント別情報 / Information by Business Segment | |
| (1) 医療分野 / Medical Business | 3,4,5 |
| ESD (Endoscopic Solutions Division)・TSD (Therapeutic Solutions Division) | |
| (2) 科学事業 / Scientific Solutions Division | 6 |
| (3) その他 / Others | 7 |
| (4) 全社消去 / Corporate Expenses | 7 |
| 3. 連結財政状態計算書 / Consolidated Statement of Financial Position | 8 |
| 4. 連結キャッシュフロー計算書 / Consolidated Statement of Cash Flows | 8 |
| 5. 会社概要 / Corporate Outline | 9 |

(本資料における留意点について)
(Notes regarding this material)

・本資料のうち、業績見通し等は、現在入手可能な情報による判断および仮定に基づいたものであり、判断や仮定に内在する不確定な要素および今後の事業運営や内外の状況変化等による変動可能性に照らし、実際の業績等が目標と大きく異なる可能性があります。

・また、これらの情報は、今後予告なしに変更されることがあります。従いまして、本情報及び資料の利用は、他の方法により入手された情報とも照合確認し、利用者の判断によって行ってくださいますようお願い致します。

・本資料利用の結果生じたいかなる損害についても、当社は一切責任を負いません。

・日本産業パートナーズ株式会社が設立した特別目的会社に対して、2021年1月1日に映像事業を譲渡しました。これに関し、2021年3月期第2四半期連結会計期間より、映像事業を非継続事業に分類し、過去に開示した以下の数値も組み替えて表示しています。
連結損益計算書：「2021年3月期第1四半期（3カ月）」

・2022年3月期より、内視鏡事業の消化器内視鏡分野に分類していた気管支鏡につきまして、治療機器事業の呼吸器科に移管しています。これに伴い、過去に開示した以下の数値も組み替えて表示しています。
セグメント別情報（ESD/TSD）：「2021年3月期第1四半期（3カ月）、第2四半期（3カ月）、第2四半期累計（6カ月）、第3四半期（3カ月）、第4四半期（3カ月）、通期」

・2021年3月期に発生したVeran Medical Technologies社、Quest Photonic Devices社の企業結合について、2022年3月期第1四半期連結会計期間及び第2四半期連結会計期間において暫定的な金額の修正を行っています。これに伴い、過去に開示した以下の数値の遡及的な修正を行っています。
連結財政状態計算書：「2021年3月期 3月31日時点」

・This material contains forward-looking statements that reflect management's current views, plans, and expectations based on information available at the time of preparation. These forward-looking statements are not guarantees of future performance and involve known and unknown risks, uncertainties, future business decisions, and other internal and external factors that may cause the Company's actual results, performance, achievements, or financial position to be materially different from any future results expressed or implied by these forward-looking statements.

・Additionally, this information is subject to change without notice. Accordingly, other information should be used in addition to this material when making investment decisions.

・Olympus Corporation assumes no responsibility for any damage resulting from the use of this material.

・Olympus Corporation split off the imaging business to a special purpose company established by Japan Industrial Partners, Inc. on January 1, 2021. In this regard, imaging division is categorized as a discontinued operation, effective Q2 of FY2021 and figures for below accounting periods are restated.
Consolidated Statements of Profit or Loss: FY2021.Q1 (3M)

・From FY2022, bronchoscopes, which were classified in the gastrointestinal endoscope segment of ESD, have been transferred into the respiratory segment of TSD. Accordingly, we restated figures for below accounting periods.
Information by Business Segment (ESD/TSD): FY2021.Q1 (3M), FY2021.Q2 (3M), FY2021.Q2 total (6M), FY2021.Q3 (3M), FY2021.Q4 (3M), FY2021 (total)

・Regarding acquisitions with Veran Medical Technologies and Quest Photonic Devices B.V. that occurred in FY2021, there were temporary revisions in amounts during Q1 and Q2 of FY2022. In line with this, the following figures disclosed in the past have been retroactively revised.
Consolidated statement of financial position: As of March 31, FY2021

1. 連結決算概要 / Consolidated Financial Summary

■ 連結損益計算書概要 / Summary of Consolidated Statements of Profit or Loss

百万円 (¥ million)

| 項目 Item | FY2021 | | | | | | FY2022 | | | | FY2022 |
|--|---------|---------|----------|---------|---------|---------|---------|---------|----------|----------------|-------------|
| | Q1 | Q2 | Q2 Total | Q3 | Q4 | Total | Q1 | Q2 | Q2 Total | Total forecast | As of Aug 5 |
| 売上高 Revenue | 136,650 | 179,850 | 316,500 | 197,084 | 216,960 | 730,544 | 191,517 | 221,542 | 413,059 | 856,000 | 830,000 |
| 売上原価 Cost of sales | 51,398 | 69,144 | 120,542 | 69,548 | 80,924 | 271,014 | 68,201 | 74,600 | 142,801 | 295,000 | 284,000 |
| 売上総利益 Gross profit | 85,252 | 110,706 | 195,958 | 127,536 | 136,036 | 459,530 | 123,316 | 146,942 | 270,258 | 561,000 | 546,000 |
| 販売費及び一般管理費 S.G.A. expenses | 80,332 | 81,126 | 161,458 | 88,719 | 106,855 | 357,032 | 95,797 | 95,662 | 191,459 | 400,000 | 401,000 |
| その他の収益および費用等 Other income and expenses etc. | -1,211 | -2,997 | -4,208 | -4,375 | -11,930 | -20,513 | 93 | -2,636 | -2,543 | -17,000 | -5,000 |
| 営業利益 Operating profit | 3,709 | 26,583 | 30,292 | 34,442 | 17,251 | 81,985 | 27,612 | 48,644 | 76,256 | 144,000 | 140,000 |
| 金融収益および費用 Finance income and costs | -1,015 | -946 | -1,961 | -855 | -2,359 | -5,175 | -660 | -1,750 | -2,410 | -5,000 | -5,000 |
| 税引前利益 Profit before tax | 2,694 | 25,637 | 28,331 | 33,587 | 14,892 | 76,810 | 26,952 | 46,894 | 73,846 | 139,000 | 135,000 |
| 法人所得税費用 Income taxes | 2,868 | -414 | 2,454 | 5,532 | 3,154 | 11,140 | 8,206 | 3,127 | 11,333 | 30,000 | 34,000 |
| 継続事業からの当期利益(損失) Profit (loss) from continuing operation | -174 | 26,051 | 25,877 | 28,055 | 11,738 | 65,670 | 18,746 | 43,767 | 62,513 | 109,000 | 101,000 |
| 非継続事業からの当期利益(損失) Profit (loss) from discontinued operation | -2,558 | -45,996 | -48,554 | -3,733 | -394 | -52,681 | - | - | - | - | - |
| 当期利益(損失) Profit (loss) | -2,732 | -19,945 | -22,677 | 24,322 | 11,344 | 12,989 | 18,746 | 43,767 | 62,513 | 109,000 | 101,000 |
| 親会社の所有者に帰属する当期利益(損失) Profit (loss) attributable to owners of parent | -2,736 | -19,966 | -22,702 | 24,326 | 11,294 | 12,918 | 18,690 | 43,707 | 62,397 | 109,000 | 101,000 |

| | | | | | | | | | | | |
|---|-------|-------|-------|-------|-------|-------|-------|-------|-------|-------|-------|
| 売上総利益率 Gross profit ratio | 62.4% | 61.6% | 61.9% | 64.7% | 62.7% | 62.9% | 64.4% | 66.3% | 65.4% | 65.5% | 65.8% |
| 販管費率 S.G.A. ratio | 58.8% | 45.1% | 51.0% | 45.0% | 49.3% | 48.9% | 50.0% | 43.2% | 46.4% | 46.7% | 48.3% |
| 営業利益率 Operating profit margin | 2.7% | 14.8% | 9.6% | 17.5% | 8.0% | 11.2% | 14.4% | 22.0% | 18.5% | 16.8% | 16.9% |
| 親会社の所有者に帰属する当期利益率 Profit (loss) attributable to owners of parent | - | - | - | 12.3% | 5.2% | 1.8% | 9.8% | 19.7% | 15.1% | 12.7% | 12.2% |

| | | | | | | | | | | | |
|-----------------------------|--------|--------|--------|--------|--------|---------|--------|--------|---------|---------|---------|
| EBITDA | 18,960 | 40,216 | 59,176 | 49,674 | 32,694 | 141,544 | 43,351 | 64,780 | 108,131 | 206,000 | 202,000 |
| EBITDAマージン EBITDA margin | 13.9% | 22.4% | 18.7% | 25.2% | 15.1% | 19.4% | 22.6% | 29.2% | 26.2% | 24.1% | 24.3% |

* FY2021Q2より映像事業を非継続事業に分類しています。非継続事業からの利益は継続事業と区分し、「売上高」から「継続事業からの当期利益(損失)」までは継続事業の金額を表示しています。/ From FY2021Q2, imaging division has been reclassified as a discontinued operation. Accordingly, profit from discontinued operation is presented separately from the profit from continuing operation. From "revenue" to "profit (loss) from continuing operation" in the above table are amounts related to continuing operation only.

■ 投資他 / Expenditures etc

百万円 (¥ million)

| 項目 Item | FY2021 | | | | | | FY2022 | | | | FY2022 |
|--|--------|--------|----------|--------|--------|--------|--------|--------|----------|----------------|-------------|
| | Q1 | Q2 | Q2 Total | Q3 | Q4 | Total | Q1 | Q2 | Q2 Total | Total forecast | As of Aug 5 |
| 減価償却費 Depreciation and amortization | 15,251 | 13,633 | 28,884 | 15,232 | 15,443 | 59,559 | 15,739 | 16,136 | 31,875 | 62,000 | 62,000 |
| 資本的支出 Capital expenditures | 14,916 | 16,673 | 31,589 | 24,532 | 42,814 | 98,935 | 16,894 | 18,136 | 35,030 | 78,000 | 78,000 |
| 研究開発支出 R&D expenditures | 17,871 | 21,146 | 39,017 | 19,584 | 23,193 | 81,794 | 20,422 | 20,338 | 40,760 | 87,000 | 84,000 |
| 開発費資本化 Capitalization of R&D expenditures | 3,415 | 3,997 | 7,412 | 4,159 | 4,563 | 16,134 | 3,803 | 4,384 | 8,187 | 18,000 | 18,000 |

* 上表の数値は継続事業の金額を表示しています。/ Amounts in the above table are related to continuing operation only.

■ 為替 / Foreign exchange

| 項目 Item | FY2021 | | | | | | FY2022 | | | | FY2022 |
|---|--------|--------|----------|--------|--------|--------|--------|--------|----------|----------------|-------------|
| | Q1 | Q2 | Q2 Total | Q3 | Q4 | Total | Q1 | Q2 | Q2 Total | Total forecast | As of Aug 5 |
| 円/USD (期中平均レート) Yen/U.S. dollar (Average rate) | 107.62 | 106.22 | 106.92 | 104.51 | 105.90 | 106.06 | 109.49 | 110.11 | 109.80 | 110 | 108 |
| 円/EUR (期中平均レート) Yen/Euro (Average rate) | 118.48 | 124.11 | 121.30 | 124.54 | 127.69 | 123.70 | 131.96 | 129.84 | 130.90 | 130 | 130 |
| 円/CNY (期中平均レート) Yen/Renminuan (Average rate) | 15.17 | 15.35 | 15.26 | 15.81 | 16.36 | 15.67 | 16.96 | 17.02 | 16.99 | 17 | 17 |

| | | | | | | | | | | | |
|--|--------|--------|--------|--------|--------|--------|--------|--------|--------|---|---|
| 売上高に対する為替影響額 FX Impact on revenue | -5,381 | -76 | -5,457 | -2,968 | 2,150 | -6,275 | 10,802 | 10,107 | 20,909 | - | - |
| 営業利益に対する為替影響額 FX Impact on operating profit | -1,732 | -2,968 | -4,700 | -939 | -1,315 | -6,954 | 429 | 3,698 | 4,127 | - | - |

* 上表の数値は継続事業の金額を表示しています。/ Amounts in the above table are related to continuing operation only.

■ 為替感応度 (年間) / Foreign exchange sensitivity (Annual basis) 億円 (¥ 100 million)

| 項目 Item | 売上高 Revenue | 営業利益 Operating profit |
|--------------------------------------|----------------|--------------------------|
| ドル (1円あたり) U.S. dollar (Per 1JPY) | 23 | 10 |
| ユーロ (1円あたり) Euro (Per 1JPY) | 16 | 7 |
| 人民元 (1円あたり) Renminuan (Per 1JPY) | 68 | 45 |

■ 従業員数 / Number of employees

| 項目 Item | FY2021 | | FY2022 | | | | |
|--|-----------------|-----------------|-----------------|--------------|--------------|--------------|--------------|
| | As of Mar 31 | As of Jun 30 | As of Jun 30 | As of Sep 30 | As of Dec 31 | As of Mar 31 | As of Mar 31 |
| 連結 Consolidated | 31,653 (18,100) | 31,191 (17,984) | 30,879 (17,891) | - | - | - | - |
| 内視鏡事業 Endoscopic Solutions Division | 13,436 (7,225) | 13,759 (7,352) | 13,693 (7,352) | - | - | - | - |
| 治療機器事業 Therapeutic Solutions Division | 8,076 (5,427) | 7,761 (5,212) | 7,674 (5,142) | - | - | - | - |
| 医療分野 Medical Business | 21,512 (12,652) | 21,520 (12,564) | 21,367 (12,494) | - | - | - | - |
| 科学事業 Scientific Solutions Division | 3,551 (2,167) | 3,623 (2,155) | 3,606 (2,145) | - | - | - | - |
| その他、全社 Others, Corporate | 6,590 (3,281) | 6,048 (3,265) | 5,906 (3,252) | - | - | - | - |

* 上表の従業員数は正社員のみでパートは含まれておりません。/ The number of temporary employees is not included in the number of employees.

* 2021年3月31日時点の従業員数には、社外転進支援制度を利用して退職する842名を含めております。/ The number of employees as of March 31, 2021 includes 842 employees who retire using the career support for external opportunity.

* () は海外従業員数です。/ () : Number of overseas employees

* FY2022より、内視鏡事業の消化器内視鏡分野に分類していた気管支鏡につきまして、治療機器事業の呼吸器科に移管しています。これに伴い、2021年3月31日時点の従業員数も組み替えて表示しています。/ From FY2022, bronchoscopes, which were classified in the gastrointestinal endoscope segment of ESD, have been transferred into the respiratory segment of TSD.

Accordingly, we restated the number of employees as of March 31, 2021.

2. セグメント別情報 / Information by Business Segment

(1) 医療分野 / Medical Business

* FY2022より、内視鏡事業の消化器内視鏡分野に分類していた気管支鏡につきまして、治療機器事業の呼吸器科に移管しています。これに伴い、FY2021Q1、Q2、Q2累計、Q3、Q4、通期の数値も組み替えて表示しています。/
From FY2022, bronchoscopes, which were classified in the gastrointestinal endoscope segment of ESD, have been transferred into the respiratory segment of TSD.
Accordingly, we restated figures for FY2021Q1, Q2, Q2 total, Q3, Q4, total.

■ ESD 損益 / Revenue and Operating profit of ESD

百万円 (¥ million)

| 項目 Item | FY2021 | | | | | | FY2022 | | | | FY2022 As of Aug 5 |
|-------------------------------------|--------|--------|----------|---------|---------|---------|---------|---------|----------|----------------|-----------------------|
| | Q1 | Q2 | Q2 Total | Q3 | Q4 | Total | Q1 | Q2 | Q2 Total | Total forecast | |
| 売上高 Revenue | 74,316 | 97,005 | 171,321 | 105,358 | 116,985 | 393,664 | 100,014 | 120,551 | 220,565 | 453,000 | 438,000 |
| 営業利益 Operating profit | 12,417 | 29,921 | 42,338 | 31,580 | 24,853 | 98,771 | 22,654 | 38,991 | 61,645 | 127,000 | 118,000 |
| その他の損益 Other income and expenses | -367 | -159 | -526 | -780 | -4,626 | -5,932 | -2,153 | -952 | -3,105 | - | - |
| 営業利益率 Operating profit margin | 16.7% | 30.8% | 24.7% | 30.0% | 21.2% | 25.1% | 22.7% | 32.3% | 27.9% | 28.0% | 26.9% |
| 売上高対前年比 Revenue (YoY) | | | | | | | 34.6% | 24.3% | 28.7% | 15.1% | |
| 営業利益対前年比 Operating profit (YoY) | | | | | | | 82.4% | 30.3% | 45.6% | 28.6% | |

■ TSD 損益 / Revenue and Operating profit of TSD

百万円 (¥ million)

| 項目 Item | FY2021 | | | | | | FY2022 | | | | FY2022 As of Aug 5 |
|-------------------------------------|--------|--------|----------|--------|--------|---------|--------|--------|----------|----------------|-----------------------|
| | Q1 | Q2 | Q2 Total | Q3 | Q4 | Total | Q1 | Q2 | Q2 Total | Total forecast | |
| 売上高 Revenue | 42,982 | 58,654 | 101,636 | 62,316 | 67,890 | 231,842 | 63,646 | 69,455 | 133,101 | 276,000 | 270,000 |
| 営業利益 Operating profit | 3,663 | 6,261 | 9,924 | 13,243 | 7,400 | 30,567 | 14,072 | 16,190 | 30,262 | 55,000 | 52,000 |
| その他の損益 Other income and expenses | -285 | -109 | -394 | -340 | -2,218 | -2,952 | 2,538 | -422 | 2,116 | - | - |
| 営業利益率 Operating profit margin | 8.5% | 10.7% | 9.8% | 21.3% | 10.9% | 13.2% | 22.1% | 23.3% | 22.7% | 19.9% | 19.3% |
| 売上高対前年比 Revenue (YoY) | | | | | | | 48.1% | 18.4% | 31.0% | 19.0% | |
| 営業利益対前年比 Operating profit (YoY) | | | | | | | 284.2% | 158.6% | 204.9% | 79.9% | |

■ 医療分野 損益 / Revenue and Operating profit of Medical Business

百万円 (¥ million)

| 項目 Item | FY2021 | | | | | | FY2022 | | | | FY2022 As of Aug 5 |
|-------------------------------------|---------|---------|----------|---------|---------|---------|---------|---------|----------|----------------|-----------------------|
| | Q1 | Q2 | Q2 Total | Q3 | Q4 | Total | Q1 | Q2 | Q2 Total | Total forecast | |
| 売上高 Revenue | 117,298 | 155,659 | 272,957 | 167,674 | 184,875 | 625,506 | 163,660 | 190,006 | 353,666 | 729,000 | 708,000 |
| 営業利益 Operating profit | 16,080 | 36,182 | 52,262 | 44,823 | 32,253 | 129,338 | 36,726 | 55,181 | 91,907 | 182,000 | 170,000 |
| その他の損益 Other income and expenses | -652 | -268 | -920 | -1,120 | -6,844 | -8,884 | 385 | -1,374 | -989 | - | - |
| 営業利益率 Operating profit margin | 13.7% | 23.2% | 19.1% | 26.7% | 17.4% | 20.7% | 22.4% | 29.0% | 26.0% | 25.0% | 24.0% |
| 売上高対前年比 Revenue (YoY) | | | | | | | 39.5% | 22.1% | 29.6% | 16.5% | |
| 営業利益対前年比 Operating profit (YoY) | | | | | | | 128.4% | 52.5% | 75.9% | 40.7% | |

■ ESD 投資他 / Expenditures etc of ESD

百万円 (¥ million)

| 項目 Item | FY2021 | | | | | | FY2022 | | | |
|--|--------|-------|----------|--------|--------|--------|--------|-------|----------|-------|
| | Q1 | Q2 | Q2 Total | Q3 | Q4 | Total | Q1 | Q2 | Q2 Total | Total |
| 減価償却費 Depreciation and amortization | 8,053 | 6,491 | 14,544 | 7,389 | 7,488 | 29,421 | 7,983 | 8,278 | 16,261 | - |
| 資本的支出 Capital expenditures | 7,964 | 8,753 | 16,717 | 10,041 | 24,120 | 50,878 | 10,504 | 8,782 | 19,286 | - |
| 研究開発支出 R&D expenditures | 6,948 | 9,124 | 16,072 | 9,093 | 9,792 | 34,957 | 9,177 | 9,033 | 18,210 | - |

■ TSD 投資他 / Expenditures etc of TSD

百万円 (¥ million)

| 項目 Item | FY2021 | | | | | | FY2022 | | | |
|--|--------|-------|----------|--------|-------|--------|--------|-------|----------|-------|
| | Q1 | Q2 | Q2 Total | Q3 | Q4 | Total | Q1 | Q2 | Q2 Total | Total |
| 減価償却費 Depreciation and amortization | 3,389 | 3,312 | 6,701 | 3,796 | 4,007 | 14,504 | 3,877 | 4,089 | 7,966 | - |
| 資本的支出 Capital expenditures | 2,526 | 3,368 | 5,894 | 11,780 | 6,692 | 24,366 | 2,835 | 4,213 | 7,048 | - |
| 研究開発支出 R&D expenditures | 4,148 | 5,084 | 9,232 | 4,482 | 5,769 | 19,483 | 4,780 | 5,061 | 9,841 | - |

■ 医療分野 投資他 / Expenditures etc of Medical Business

百万円 (¥ million)

| 項目 Item | FY2021 | | | | | | FY2022 | | | |
|--|--------|--------|----------|--------|--------|--------|--------|--------|----------|-------|
| | Q1 | Q2 | Q2 Total | Q3 | Q4 | Total | Q1 | Q2 | Q2 Total | Total |
| 減価償却費 Depreciation and amortization | 11,442 | 9,803 | 21,245 | 11,185 | 11,495 | 43,925 | 11,860 | 12,367 | 24,227 | - |
| 資本的支出 Capital expenditures | 10,490 | 12,121 | 22,611 | 21,821 | 30,812 | 75,244 | 13,339 | 12,995 | 26,334 | - |
| 研究開発支出 R&D expenditures | 11,096 | 14,208 | 25,304 | 13,575 | 15,561 | 54,440 | 13,957 | 14,094 | 28,051 | - |

■ ESD 地域別売上高 / Revenue by Region of ESD

百万円 (¥ million)

| 項目 Item | FY2021 | | | | | | FY2022 | | | |
|-------------------------------|--------|--------|----------|---------|---------|---------|---------|---------|----------|-------|
| | Q1 | Q2 | Q2 Total | Q3 | Q4 | Total | Q1 | Q2 | Q2 Total | Total |
| 日本 Japan | 9,832 | 15,350 | 25,182 | 14,476 | 20,490 | 60,148 | 13,543 | 17,722 | 31,265 | - |
| 北米 North America | 26,385 | 31,304 | 57,689 | 35,395 | 39,422 | 132,506 | 37,353 | 39,444 | 76,797 | - |
| 欧州 Europe | 19,157 | 24,170 | 43,329 | 29,079 | 28,704 | 101,111 | 25,060 | 29,493 | 54,553 | - |
| 中国 China | 11,378 | 16,430 | 27,808 | 16,107 | 16,158 | 60,073 | 13,717 | 21,118 | 34,835 | - |
| アジア・オセアニア Asia and Oceania | 6,465 | 8,219 | 14,684 | 8,347 | 9,562 | 32,593 | 8,590 | 10,395 | 18,985 | - |
| その他 Others | 1,099 | 1,532 | 2,629 | 1,954 | 2,649 | 7,233 | 1,751 | 2,379 | 4,130 | - |
| 合計 Total | 74,316 | 97,005 | 171,321 | 105,358 | 116,985 | 393,664 | 100,014 | 120,551 | 220,565 | - |

■ TSD 地域別売上高 / Revenue by Region of TSD

百万円 (¥ million)

| 項目 Item | FY2021 | | | | | | FY2022 | | | |
|-------------------------------|--------|--------|----------|--------|--------|---------|--------|--------|----------|-------|
| | Q1 | Q2 | Q2 Total | Q3 | Q4 | Total | Q1 | Q2 | Q2 Total | Total |
| 日本 Japan | 8,566 | 10,364 | 18,930 | 11,232 | 11,379 | 41,541 | 10,213 | 11,946 | 22,159 | - |
| 北米 North America | 13,382 | 21,042 | 34,424 | 21,214 | 23,287 | 78,925 | 23,945 | 25,167 | 49,112 | - |
| 欧州 Europe | 10,587 | 14,442 | 25,029 | 16,420 | 17,737 | 59,185 | 16,542 | 16,277 | 32,819 | - |
| 中国 China | 6,199 | 7,600 | 13,799 | 7,589 | 9,594 | 30,982 | 6,952 | 9,778 | 16,730 | - |
| アジア・オセアニア Asia and Oceania | 3,715 | 4,687 | 8,402 | 4,980 | 4,911 | 18,293 | 5,187 | 5,249 | 10,436 | - |
| その他 Others | 533 | 519 | 1,052 | 881 | 982 | 2,916 | 807 | 1,038 | 1,845 | - |
| 合計 Total | 42,982 | 58,654 | 101,636 | 62,316 | 67,890 | 231,842 | 63,646 | 69,455 | 133,101 | - |

■ 医療分野 地域別売上高 / Revenue by Region of Medical Business

百万円 (¥ million)

| 項目 Item | FY2021 | | | | | | FY2022 | | | |
|-------------------------------|---------|---------|----------|---------|---------|---------|---------|---------|----------|-------|
| | Q1 | Q2 | Q2 Total | Q3 | Q4 | Total | Q1 | Q2 | Q2 Total | Total |
| 日本 Japan | 18,398 | 25,714 | 44,112 | 25,708 | 31,869 | 101,689 | 23,756 | 29,668 | 53,424 | - |
| 北米 North America | 39,767 | 52,346 | 92,113 | 56,609 | 62,709 | 211,431 | 61,298 | 64,611 | 125,909 | - |
| 欧州 Europe | 29,744 | 38,612 | 68,358 | 45,499 | 46,441 | 160,296 | 41,602 | 45,770 | 87,372 | - |
| 中国 China | 17,577 | 24,030 | 41,607 | 23,696 | 25,752 | 91,055 | 20,669 | 30,896 | 51,565 | - |
| アジア・オセアニア Asia and Oceania | 10,180 | 12,906 | 23,086 | 13,327 | 14,473 | 50,886 | 13,777 | 15,644 | 29,421 | - |
| その他 Others | 1,632 | 2,051 | 3,681 | 2,835 | 3,631 | 10,149 | 2,558 | 3,417 | 5,975 | - |
| 合計 Total | 117,298 | 155,659 | 272,957 | 167,674 | 184,875 | 625,506 | 163,660 | 190,006 | 353,666 | - |

■ ESDサブセグメント別売上占有率 / Sub-segment Sales Ratio within ESD

(FY2022 Q2 Total)

| 消化器内視鏡 Gastrointestinal Endoscope | 外科内視鏡 Surgical Endoscope | 医療サービス Medical Service |
|--------------------------------------|-----------------------------|---------------------------|
| 約 Approx. 55% | 約 Approx. 10% | 約 Approx. 30% |

■ TSDサブセグメント別売上占有率 / Sub-segment Sales Ratio within TSD

(FY2022 Q2 Total)

| 消化器科 (処置具) GI-Endotherapy | 泌尿器科 Urology | 呼吸器科 Respiratory | その他の治療領域 Other Therapeutic Areas |
|------------------------------|------------------|---------------------|-------------------------------------|
| 約 Approx. 30% | 約 Approx. 30% | 約 Approx. 15% | 約 Approx. 25% |

* 四捨五入のため、合計値が100%にならないことがあります。 / Due to rounding, the total may not add up to 100%.

■ 現地通貨別成長率 / Growth Rate of Medical Segment on Constant Currency Basis
(為替影響調整後前年同期比 / After foreign exchange adjustment YoY)

| 項目 Item | FY2022 | | | | | | | | |
|-------------------------------|-------------------------------|---------------------|-------|-------|----------|-------|-------|-------|---|
| | Q1 | | Q2 | | Q2 Total | | Total | | |
| ESD | 日本 Japan | 38% | (38%) | 15% | (15%) | 24% | (24%) | - | |
| | 北米 North America | 38% | (38%) | 22% | (22%) | 29% | (29%) | - | |
| | 欧州 Europe | 18% | (17%) | 15% | (15%) | 16% | (16%) | - | |
| | 中国 China | 8% | (8%) | 16% | (16%) | 13% | (13%) | - | |
| | アジア・オセアニア Asia and Oceania | 21% | (21%) | 20% | (20%) | 20% | (20%) | - | |
| | 分野計 Total | 27% | (27%) | 18% | (18%) | 22% | (22%) | - | |
| | TSD | 日本 Japan | 19% | (19%) | 15% | (15%) | 17% | (17%) | - |
| | | 北米 North America | 75% | (67%) | 15% | (12%) | 38% | (33%) | - |
| 欧州 Europe | | 40% | (40%) | 7% | (7%) | 21% | (21%) | - | |
| 中国 China | | 1% | (1%) | 16% | (16%) | 9% | (9%) | - | |
| アジア・オセアニア Asia and Oceania | | 26% | (26%) | 6% | (6%) | 15% | (15%) | - | |
| 分野計 Total | | 40% | (37%) | 13% | (12%) | 24% | (23%) | - | |
| 医療分野 Medical Business | | 日本 Japan | 29% | (29%) | 15% | (15%) | 21% | (21%) | - |
| | | 北米 North America | 50% | (48%) | 19% | (18%) | 33% | (31%) | - |
| | 欧州 Europe | 26% | (25%) | 12% | (12%) | 18% | (18%) | - | |
| | 中国 China | 6% | (6%) | 16% | (16%) | 11% | (11%) | - | |
| | アジア・オセアニア Asia and Oceania | 23% | (23%) | 15% | (15%) | 18% | (18%) | - | |
| | 分野計 Total | 32% | (31%) | 16% | (16%) | 23% | (22%) | - | |

* FY2022より、内視鏡事業の消化器内視鏡分野に分類していた気管支鏡につきまして、治療機器事業の呼吸器科に移管しています。

これに伴い、FY2022Q1以降は組替後の成長率を表示、FY2021の成長率は非開示といたします。/

From FY2022, bronchoscopes, which were classified in the gastrointestinal endoscope segment of ESD, have been transferred into the respiratory segment of TSD. Accordingly, the reclassified growth rates are shown from the Q1 of FY2022. Growth rates for FY2021 are not disclosed.

* ():Arc Medical Design社、Veran Medical Technologies社、Quest Photonic Devices社の買収による売上の影響を除く、オーガニックベース /

():Organic Basis, excluding the impact of sales from the acquisitions of Arc Medical Design Limited, Veran Medical Technologies, and Quest Photonic Devices B.V.

■ サブセグメント別成長率 / Growth Rate by Sub-segment
(為替影響調整後前年同期比 / After foreign exchange adjustment YoY)

| 項目 Item | FY2022 | | | | | | | |
|------------|--------------------------------------|-----|-------|-----|----------|-----|-------|---|
| | Q1 | | Q2 | | Q2 Total | | Total | |
| ESD | 消化器内視鏡 Gastrointestinal Endoscope | 38% | (38%) | 23% | (23%) | 29% | (29%) | - |
| | 外科内視鏡 Surgical Endoscope | 28% | (27%) | 17% | (17%) | 21% | (21%) | - |
| | 医療サービス Medical Service | 11% | (11%) | 10% | (10%) | 11% | (11%) | - |
| | 分野計 Total | 27% | (27%) | 18% | (18%) | 22% | (22%) | - |
| TSD | 消化器科 (処置具) GI-Endotherapy | 32% | (32%) | 9% | (9%) | 19% | (19%) | - |
| | 泌尿器科 Urology | 60% | (60%) | 13% | (13%) | 32% | (32%) | - |
| | 呼吸器科 Respiratory | 33% | (19%) | 29% | (21%) | 31% | (20%) | - |
| | その他の治療領域 Other Therapeutic Areas | 34% | (34%) | 9% | (9%) | 20% | (20%) | - |
| | 分野計 Total | 40% | (37%) | 13% | (12%) | 24% | (23%) | - |

* ():Arc Medical Design社、Veran Medical Technologies社、Quest Photonic Devices社の買収による売上の影響を除く、オーガニックベース /

():Organic Basis, excluding the impact of sales from the acquisitions of Arc Medical Design Limited, Veran Medical Technologies, and Quest Photonic Devices B.V.

2. セグメント別情報 / Information by Business Segment

(2) 科学事業 / Scientific Solutions Division

■ 損益 / Revenue and Operating profit

百万円 (¥ million)

| 項目 Item | FY2021 | | | | | | FY2022 | | | | FY2022 As of Aug 5 |
|-------------------------------------|--------|--------|----------|--------|--------|--------|--------|--------|----------|----------------|-----------------------|
| | Q1 | Q2 | Q2 Total | Q3 | Q4 | Total | Q1 | Q2 | Q2 Total | Total forecast | |
| 売上高 Revenue | 17,757 | 22,555 | 40,312 | 26,629 | 28,920 | 95,861 | 24,829 | 28,332 | 53,161 | 114,000 | 109,000 |
| 営業損益 Operating profit (loss) | -1,604 | 1,827 | 223 | 2,733 | 1,993 | 4,949 | 1,873 | 4,612 | 6,485 | 15,500 | 13,000 |
| その他の損益 Other income and expenses | -313 | 349 | 36 | -17 | -1,263 | -1,244 | -183 | -105 | -288 | - | - |
| 営業利益率 Operating profit margin | - | 8.1% | 0.6% | 10.3% | 6.9% | 5.2% | 7.5% | 16.3% | 12.2% | 13.6% | 11.9% |

| | | | | | | | | | | |
|------------------------------------|---|---|---|---|---|---|-------|--------|---------|--------|
| 売上高対前年比 Revenue (YoY) | / | / | / | / | / | / | 39.8% | 25.6% | 31.9% | 18.9% |
| 営業利益対前年比 Operating profit (YoY) | / | / | / | / | / | / | - | 152.4% | 2808.1% | 213.2% |

■ 投資他 / Expenditures etc

百万円 (¥ million)

| 項目 Item | FY2021 | | | | | | FY2022 | | | |
|--|--------|-------|----------|-------|-------|-------|--------|-------|----------|-------|
| | Q1 | Q2 | Q2 Total | Q3 | Q4 | Total | Q1 | Q2 | Q2 Total | Total |
| 減価償却費 Depreciation and amortization | 1,699 | 1,783 | 3,482 | 1,998 | 1,833 | 7,313 | 1,716 | 1,791 | 3,507 | - |
| 資本的支出 Capital expenditures | 1,367 | 1,733 | 3,100 | 1,278 | 4,720 | 9,098 | 1,425 | 2,085 | 3,510 | - |
| 研究開発支出 R&D expenditures | 1,738 | 2,296 | 4,034 | 1,929 | 2,999 | 8,962 | 1,971 | 2,705 | 4,676 | - |

■ 地域別売上高 / Revenue by Region

百万円 (¥ million)

| 項目 Item | FY2021 | | | | | | FY2022 | | | |
|-------------------------------|--------|--------|----------|--------|--------|--------|--------|--------|----------|-------|
| | Q1 | Q2 | Q2 Total | Q3 | Q4 | Total | Q1 | Q2 | Q2 Total | Total |
| 日本 Japan | 2,061 | 3,280 | 5,341 | 3,065 | 6,393 | 14,798 | 2,526 | 4,393 | 6,919 | - |
| 北米 North America | 4,592 | 5,853 | 10,445 | 6,869 | 8,070 | 25,384 | 6,920 | 7,543 | 14,463 | - |
| 欧州 Europe | 3,178 | 4,212 | 7,389 | 5,801 | 5,941 | 19,132 | 4,413 | 5,378 | 9,791 | - |
| 中国 China | 4,353 | 5,173 | 9,526 | 5,929 | 3,822 | 19,277 | 5,509 | 5,514 | 11,023 | - |
| アジア・オセアニア Asia and Oceania | 2,724 | 2,965 | 5,689 | 3,525 | 3,238 | 12,452 | 3,860 | 3,808 | 7,668 | - |
| その他 Others | 849 | 1,072 | 1,922 | 1,440 | 1,456 | 4,818 | 1,601 | 1,696 | 3,297 | - |
| 合計 Total | 17,757 | 22,555 | 40,312 | 26,629 | 28,920 | 95,861 | 24,829 | 28,332 | 53,161 | - |

■ サブセグメント別売上占有率 / Sub-segment Sales Ratio

(FY2022 Q2 Total)

| ライフサイエンス Life Science | 産業 Industrial |
|--------------------------|----------------------|
| 約 40% Approx. 40% | 約 60% Approx. 60% |

■ サブセグメント別成長率 / Growth Rate by Sub-segment

(為替影響調整後前年同期比 / After foreign exchange adjustment YoY)

| 項目 Item | FY2021 | | | | | | FY2022 | | | |
|--------------------------|--------|----|----------|----|----|-------|--------|-----|----------|-------|
| | Q1 | Q2 | Q2 Total | Q3 | Q4 | Total | Q1 | Q2 | Q2 Total | Total |
| ライフサイエンス Life Science | / | / | / | / | / | / | 22% | 13% | 16% | - |
| 産業 Industrial | / | / | / | / | / | / | 39% | 26% | 32% | - |
| 分野計 Total | / | / | / | / | / | / | 32% | 20% | 25% | - |

2. セグメント別情報 / Information by Business Segment

(3) その他 / Others

■ 損益 / Revenue and Operating profit

百万円 (¥ million)

| 項目 Item | FY2021 | | | | | | FY2022 | | | | FY2022 As of Aug 5 |
|-------------------------------------|--------|-------|----------|-------|-------|-------|--------|-------|----------|----------------|-----------------------|
| | Q1 | Q2 | Q2 Total | Q3 | Q4 | Total | Q1 | Q2 | Q2 Total | Total forecast | |
| 売上高 Revenue | 1,595 | 1,636 | 3,231 | 2,781 | 3,165 | 9,177 | 3,028 | 3,204 | 6,232 | 13,000 | 13,000 |
| 営業損益 Operating profit (losses) | -518 | -443 | -961 | -570 | 849 | -682 | -565 | -573 | -1,138 | -2,500 | -4,000 |
| その他の損益 Other income and expenses | 2 | -26 | -24 | 22 | 1,534 | 1,532 | 31 | -406 | -375 | - | - |
| 営業利益率 Operating profit margin | - | - | - | - | - | - | - | - | - | - | - |

| | | | | | | | | | | |
|------------------------------------|--|--|--|--|--|--|-------|-------|-------|-------|
| 売上高対前年比 Revenue (YoY) | | | | | | | 89.8% | 95.8% | 92.9% | 41.7% |
| 営業利益対前年比 Operating profit (YoY) | | | | | | | - | - | - | - |

* FY2021Q2より映像事業を非継続事業に分類したことに伴い、FY2021Q1の数値も組み替えて表示しています。/

From FY2021Q2, imaging division has been reclassified as a discontinued operation. Accordingly, we restated figures for FY2021Q1.

■ 地域別売上高 / Revenue by Region

百万円 (¥ million)

| 項目 Item | FY2021 | | | | | | FY2022 | | | |
|-------------------------------|--------|-------|----------|-------|-------|-------|--------|-------|----------|-------|
| | Q1 | Q2 | Q2 Total | Q3 | Q4 | Total | Q1 | Q2 | Q2 Total | Total |
| 日本 Japan | 1,504 | 1,520 | 3,024 | 2,003 | 1,940 | 6,967 | 1,812 | 2,075 | 3,887 | - |
| 北米 North America | 24 | 33 | 57 | 52 | 55 | 164 | 61 | 38 | 99 | - |
| 欧州 Europe | 13 | 12 | 25 | 669 | 1,105 | 1,799 | 1,091 | 992 | 2,083 | - |
| 中国 China | 2 | 4 | 6 | 4 | 12 | 22 | 14 | 2 | 16 | - |
| アジア・オセアニア Asia and Oceania | 52 | 67 | 119 | 53 | 53 | 225 | 50 | 97 | 147 | - |
| その他 Others | - | - | - | - | - | - | - | - | - | - |
| 合計 Total | 1,595 | 1,636 | 3,231 | 2,781 | 3,165 | 9,177 | 3,028 | 3,204 | 6,232 | - |

* FY2021Q2より映像事業を非継続事業に分類したことに伴い、FY2021Q1の数値も組み替えて表示しています。/

From FY2021Q2, imaging division has been reclassified as a discontinued operation. Accordingly, we restated figures for FY2021Q1.

(4) 全社消去 / Corporate expenses

■ 損益 / Revenue and Operating profit

百万円 (¥ million)

| 項目 Item | FY2021 | | | | | | FY2022 | | | | FY2022 As of Aug 5 |
|-------------------------------------|---------|---------|----------|---------|---------|---------|---------|---------|----------|----------------|-----------------------|
| | Q1 | Q2 | Q2 Total | Q3 | Q4 | Total | Q1 | Q2 | Q2 Total | Total forecast | |
| 売上高 Revenue | - | - | - | - | - | - | - | - | - | - | - |
| 営業損益 Operating profit (losses) | -10,249 | -10,983 | -21,232 | -12,544 | -17,844 | -51,620 | -10,422 | -10,576 | -20,998 | -51,000 | -39,000 |
| その他の損益 Other income and expenses | -276 | -3,105 | -3,381 | -3,386 | -5,745 | -12,512 | -175 | -1,115 | -1,290 | - | - |

* FY2021Q2より映像事業を非継続事業に分類したことに伴い、FY2021Q1の数値も組み替えて表示しています。/

From FY2021Q2, imaging division has been reclassified as a discontinued operation. Accordingly, we restated figures for FY2021Q1.

■ 投資他 (その他・全社消去) / Expenditures etc (Others, Corporate expenses)

百万円 (¥ million)

| 項目 Item | FY2021 | | | | | | FY2022 | | | |
|--|--------|-------|----------|-------|-------|--------|--------|-------|----------|-------|
| | Q1 | Q2 | Q2 Total | Q3 | Q4 | Total | Q1 | Q2 | Q2 Total | Total |
| 減価償却費 Depreciation and amortization | 2,110 | 2,047 | 4,157 | 2,049 | 2,115 | 8,321 | 2,163 | 1,978 | 4,141 | - |
| 資本的支出 Capital expenditures | 3,059 | 2,819 | 5,878 | 1,433 | 7,282 | 14,593 | 2,130 | 3,056 | 5,186 | - |
| 研究開発支出 R&D expenditures | 5,037 | 4,642 | 9,679 | 4,080 | 4,633 | 18,392 | 4,494 | 3,539 | 8,033 | - |

3. 連結財政状態計算書 / Consolidated statement of financial position

百万円 (¥ million)

| 項目 Item | FY2021 | | | | FY2022 | | | |
|--|-----------------|-----------------|-----------------|-----------------|-----------------|-----------------|-----------------|-----------------|
| | As of Jun 30 | As of Sep 30 | As of Dec 31 | As of Mar 31 | As of Jun 30 | As of Sep 30 | As of Dec 31 | As of Mar 31 |
| 資産 Assets | 1,099,081 | 1,073,542 | 1,105,221 | 1,183,330 | 1,144,606 | 1,185,302 | - | - |
| 流動資産 Current assets | 604,400 | 571,170 | 553,935 | 580,073 | 513,399 | 552,314 | - | - |
| 現金及び現金同等物 Cash and cash equivalents | 270,506 | 185,618 | 163,420 | 217,478 | 168,713 | 193,435 | - | - |
| 棚卸資産 Inventories | 183,318 | 160,857 | 159,457 | 158,895 | 164,057 | 166,047 | - | - |
| 売却目的で保有する資産 Assets held for sale | 6,100 | 32,638 | 25,027 | 117 | 435 | - | - | - |
| その他 Others | 144,476 | 192,057 | 206,031 | 203,583 | 180,194 | 192,832 | - | - |
| 非流動資産 Non-current assets | 494,681 | 502,372 | 551,286 | 603,257 | 631,207 | 632,988 | - | - |
| 負債 Liabilities | 737,126 | 745,956 | 749,384 | 787,850 | 743,228 | 738,071 | - | - |
| 流動負債 Current liabilities | 344,410 | 303,612 | 295,618 | 328,391 | 282,670 | 288,236 | - | - |
| 売却目的で保有する資産に直接関連する負債 Liabilities directly associated with assets held for sale | 4,093 | 28,996 | 25,027 | - | 1,056 | - | - | - |
| 非流動負債 Non-current liabilities | 392,716 | 442,344 | 453,766 | 459,459 | 460,558 | 449,835 | - | - |
| 資本 Equity | 361,955 | 327,586 | 355,837 | 395,480 | 401,378 | 447,231 | - | - |
| 親会社の所有者に帰属する持分 Total equity attributable to owners of parent | 360,910 | 326,520 | 354,775 | 394,326 | 400,356 | 446,149 | - | - |
| その他 Others | 1,045 | 1,066 | 1,062 | 1,154 | 1,022 | 1,082 | - | - |
| 有利子負債 Interest-bearing debt | 395,920 | 382,732 | 359,491 | 355,264 | 335,070 | 335,374 | - | - |
| 純有利子負債 Net debt | 125,414 | 197,114 | 196,071 | 137,786 | 166,357 | 141,939 | - | - |
| 自己資本比率 Equity ratio | 32.8% | 30.4% | 32.1% | 33.3% | 35.0% | 37.6% | - | - |

* FY2021に発生したVeran Medical Technologies社、Quest Photonic Devices社の企業結合について、FY2022Q1及びQ2において暫定的な金額の修正を行っています。これに伴い、FY2021 3月31日時点の数値を遡及して修正しています。
Regarding acquisitions with Veran Medical Technologies and Quest Photonic Devices B.V. that occurred in FY2021, there were temporary revisions in amounts during Q1 and Q2 of FY2022. In line with this, the figures as of March 31, FY2021 have been retroactively revised.

4. 連結キャッシュ・フロー計算書 / Consolidated statement of cash flows

百万円 (¥ million)

| 項目 Item | FY2021 | | | | | FY2022 | | | | |
|---|---------|---------|---------|---------|----------|---------|---------|----|----|-------|
| | Q1 | Q2 | Q3 | Q4 | Total | Q1 | Q2 | Q3 | Q4 | Total |
| 営業キャッシュ・フロー Cash flows from operating activities | 8,388 | 29,061 | 51,573 | 35,100 | 124,122 | 23,681 | 45,152 | - | - | - |
| 投資キャッシュ・フロー Cash flows from investing activities | -12,291 | -57,924 | -44,795 | -3,908 | -118,918 | -33,503 | -16,950 | - | - | - |
| フリー・キャッシュ・フロー Free cash flows | -3,903 | -28,863 | 6,778 | 31,192 | 5,204 | -9,822 | 28,202 | - | - | - |
| 財務キャッシュ・フロー Cash flows from financing activities | 111,818 | -30,591 | -29,256 | -11,171 | 40,800 | -38,955 | -5,123 | - | - | - |

6. 会社概要 / Corporate Outline

■ 会社概要 / Corporate outline

2021年9月30日現在
As of Sep 30, 2021

| | |
|---------------------------|--|
| 会社名 | オリンパス株式会社 |
| Company name | Olympus Corporation |
| 上場市場 | 東証一部 |
| Market | 1st section of Tokyo Stock Exchange |
| 銘柄コード | 7733 |
| Stock code | ISIN: JP3201200007 |
| 設立年月日 | 1919年10月12日 |
| Established | October 12, 1919 |
| 資本金（百万円） | 124,643 |
| Capital (¥ million) | |
| 従業員数 | 30,879 |
| Headcount | |
| グループ会社数 | 100（本社除く / excluding Olympus Corporation） |
| Number of group companies | |
| 本社 | 〒163-0914 東京都新宿区西新宿2丁目3番1号 新宿モリス |
| Head Office | https://www.olympus.co.jp/ Shinjuku Monolith, 3-1 Nishi-Shinjuku 2-chome, Shinjuku-ku, Tokyo 163-0914, Japan |
| 事業場 | https://www.olympus-global.com/network/ 八王子市（東京都）、上伊那郡（長野県）、西白河郡（福島県） |
| Factory, R&D Center | Hachioji Tokyo Met., Kami Ina Nagano Pref., Nishi Shirakawa Fukushima Pref. |
| 支店 | 札幌、名古屋、大阪、広島、福岡、神戸 |
| Branch Offices | Sapporo, Nagoya, Osaka, Hiroshima, Fukuoka, Kobe |
| 営業所 | 新潟、松本、静岡、金沢、京都、岡山、松山、鹿児島 |
| Sales Offices | Niigata, Matsumoto, Shizuoka, Kanazawa, Kyoto, Okayama, Matsuyama, Kagoshima |
| 海外拠点 | アメリカ、ドイツ、イギリス、中国、シンガポールほか |
| Overseas Offices | USA, Germany, UK, China, Singapore etc |

■ 株式状況 / Stock information

2021年9月30日現在
As of Sep 30, 2021

| | |
|-----------------------------------|---------------|
| 発行可能株式総数（株） | 4,000,000,000 |
| Total Number of Authorized Shares | |
| 発行済株式総数（株） | 1,299,294,333 |
| Number of Shares Issued (Shares) | |

■ 株式の分布状況 / Shareholder Distribution

2021年9月30日現在
As of Sep 30, 2021

| | 所有株式数 Number of shares | 所有株式数の割合 Shareholders ratio |
|--------------------------------------|---------------------------|--------------------------------|
| 金融機関 | 514,488,196 | 39.6% |
| Japanese financial institution | | |
| 証券会社 | 9,839,020 | 0.8% |
| Japanese securities firms | | |
| その他国内法人 | 32,243,567 | 2.5% |
| Other Japanese corporations | | |
| 外国人 | 677,083,453 | 52.1% |
| Foreign institutions and individuals | | |
| 個人・その他 | 51,991,749 | 4.0% |
| Jananese individuals and others | | |
| 自己株式 | 13,648,348 | 1.1% |
| Treasury stock | | |
| 合計 | 1,299,294,333 | 100.0% |
| Total | | |